{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:37:27Z","timestamp":1783633047205,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ejca.2022.03.027","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T04:06:39Z","timestamp":1651118799000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)"],"prefix":"10.1016","volume":"169","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9340-3962","authenticated-orcid":false,"given":"Jiarui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuejuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihebali","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enxiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxian","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianglin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songhua","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.03.027_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2022.03.027_bib2","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ejca.2022.03.027_bib3","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10555-015-9573-1","article-title":"Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors","volume":"34","author":"Jimenez-Fonseca","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ejca.2022.03.027_bib4","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/ecc.12085","article-title":"Quality of life, resource utilisation and health economics assessment in advanced neuroendocrine tumours: a systematic review","volume":"22","author":"Chau","year":"2013","journal-title":"Eur J Cancer Care"},{"key":"10.1016\/j.ejca.2022.03.027_bib5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours","volume":"9","author":"Modlin","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.03.027_bib6","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/ijc.31957","article-title":"Association between progression-free survival and patients' quality of life in cancer clinical trials","volume":"144","author":"Hwang","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2022.03.027_bib7","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/jamainternmed.2018.4710","article-title":"Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology: a systematic review and quantitative analysis","volume":"178","author":"Kovic","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ejca.2022.03.027_bib8","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jhep.2012.11.019","article-title":"The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma","volume":"58","author":"Diouf","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejca.2022.03.027_bib9","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.3748\/wjg.v26.i25.3686","article-title":"Quality of life in patients with gastroenteropancreatic tumours: a systematic literature review","volume":"26","author":"Watson","year":"2020","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejca.2022.03.027_bib10","doi-asserted-by":"crossref","first-page":"R267","DOI":"10.1530\/ERC-20-0066","article-title":"Health-related quality of life in neuroendocrine neoplasia: a critical review","volume":"27","author":"White","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ejca.2022.03.027_bib11","doi-asserted-by":"crossref","first-page":"42076","DOI":"10.18632\/oncotarget.14942","article-title":"Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2022.03.027_bib12","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S1470-2045(20)30493-9","article-title":"Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.03.027_bib13","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/S1470-2045(20)30496-4","article-title":"Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.03.027_bib14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2022.03.027_bib15","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/annonc\/mdn417","article-title":"Validation of the simplified Chinese version of EORTC QLQ-C30 from the measurements of five types of inpatients with cancer","volume":"19","author":"Wan","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.03.027_bib16","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ejca.2005.10.025","article-title":"Development of a disease-specific Quality of Life questionnaire module for patients with gastrointestinal neuroendocrine tumours","volume":"42","author":"Davies","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.03.027_bib17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.03.027_bib18","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1470-2045(17)30618-6","article-title":"Maintaining quality of life for patients with neuroendocrine tumours","volume":"18","author":"Walter","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.03.027_bib19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ygyno.2018.03.058","article-title":"Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer","volume":"150","author":"Liu","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2022.03.027_bib20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3322\/caac.21493","article-title":"Gastroenteropancreatic neuroendocrine tumors","volume":"68","author":"Cives","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2022.03.027_bib21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MPA.0b013e3182328045","article-title":"Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population","volume":"41","author":"Beaumont","year":"2012","journal-title":"Pancreas"},{"key":"10.1016\/j.ejca.2022.03.027_bib22","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s11523-016-0462-5","article-title":"Patient-reported outcomes and quality of life with sunitinib versus placebo for pancreatic neuroendocrine tumors: results from an international phase III trial","volume":"11","author":"Vinik","year":"2016","journal-title":"Target Oncol"},{"key":"10.1016\/j.ejca.2022.03.027_bib23","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S1470-2045(17)30471-0","volume":"18","author":"Pavel","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.03.027_bib24","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.03.027_bib25","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","article-title":"Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with (177)Lu-dotatate in the phase III NETTER-1 trial","volume":"36","author":"Strosberg","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.03.027_bib26","doi-asserted-by":"crossref","first-page":"71699","DOI":"10.18632\/oncotarget.17599","article-title":"A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in China","volume":"8","author":"Fan","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2022.03.027_bib27","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1200\/JCO.2016.68.2518","article-title":"Updating the American society of clinical oncology value framework: revisions and reflections in response to comments received","volume":"34","author":"Schnipper","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.03.027_bib28","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.03.027_bib29","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jval.2018.09.2842","article-title":"A review of patient-reported outcomes labeling for oncology drugs approved by the FDA and the EMA (2012-2016)","volume":"22","author":"Gnanasakthy","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.ejca.2022.03.027_bib30","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study","volume":"18","author":"Halperin","year":"2017","journal-title":"Lancet Oncol"}],"updated-by":[{"DOI":"10.1016\/j.ejca.2022.10.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000}}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922001721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922001721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T01:19:16Z","timestamp":1678670356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922001721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":30,"alternative-id":["S0959804922001721"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.03.027","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ejca.2022.10.001","asserted-by":"object"}]},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.03.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}